Dr Reddys Laboratories (RDY) Short term Debt (2009 - 2026)

Dr Reddys Laboratories has reported Short term Debt for 18 years, with the latest figure at $609.3 million in Q2 2026.

• On a quarterly basis, Short term Debt rose 35.87% year-over-year to $609.3 million in Q2 2026; TTM through Jun 2026 was $609.3 million, a 35.87% increase from a year earlier, with the FY2026 full-year figure at $670.0 million, changed N/A from the prior year.
• Short term Debt was $609.3 million for Q2 2026 at Dr Reddys Laboratories, down from $646.9 million in the prior quarter.
• The five-year high for Short term Debt was $646.9 million in Q1 2026, with the low at $70.7 million in Q3 2023.
• Average Short term Debt over 5 years is $343.1 million, with a median of $363.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Short term Debt plunged 66.09% in 2023, then surged 574.79% in 2024.
• Over 5 years, Short term Debt stood at $139.7 million in 2022, then advanced by 6.13% to $148.2 million in 2023, then surged by 238.76% to $502.2 million in 2024, then rose by 12.45% to $564.7 million in 2025, then increased by 7.91% to $609.3 million in 2026.
• The last three Short term Debt figures came in at $609.3 million (Q2 2026), $646.9 million (Q1 2026), and $564.7 million (Q4 2025), per Business Quant data.